MARKET

CTMX

CTMX

Cytomx Therapeutics Inc
NASDAQ
1.410
+0.020
+1.44%
After Hours: 1.409 -0.001 -0.09% 16:38 12/01 EST
OPEN
1.370
PREV CLOSE
1.390
HIGH
1.430
LOW
1.360
VOLUME
206.14K
TURNOVER
0
52 WEEK HIGH
3.020
52 WEEK LOW
1.040
MARKET CAP
94.45M
P/E (TTM)
-3.1181
1D
5D
1M
3M
1Y
5Y
AstraZeneca (AZN) to Discontinue Two Studies on Lokelma
NASDAQ · 1d ago
Annovis Bio (ANVS) Stock Surges 38% in a Month: Here's Why
NASDAQ · 1d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: CytomX Therapeutics (CTMX), BiomX (PHGE) and Moderna (MRNA)
TipRanks · 1d ago
AbbVie-Immunogen deal lifts ADC-focused biotechs
Abbvie agreed to acquire cancer drugmaker immunogen for $10.1b in cash. Immunogen is a developer of a new class of cancer drugs called antibody-drug conjugates. The deal lifts the shares of smaller adc-focused biotechs.
Seeking Alpha · 2d ago
Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND
NASDAQ · 2d ago
Asia-Pacific stocks mixed as traders digest China's PMI data, eyes on US price update
Asia-pacific stocks mixed as traders digest china's pmi data, eyes on us price update. Japan's housing starts drop by 6.3% year-on-year in october 2023. China's manufacturing and services pmis were weaker than expected. All three major indexes in the u.s. Ended flat on wednesday.
Seeking Alpha · 2d ago
Emergent (EBS) Gets $75M BARDA Contract for Anthrax Vaccine
NASDAQ · 3d ago
Immunovant (IMVT) Up on Positive Initial IMVT-1402 MAD Study Data
NASDAQ · 3d ago
More
About CTMX
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing a class of investigational conditionally activated therapeutics, based on its Probody technology platform, for the treatment of cancer. Its Probody technology platform is designed to enable conditional activation of antibody-based drugs in the tumor microenvironment while minimizing drug activity in healthy tissues and in circulation. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates, T-cell engaging bispecific antibodies (TCBs), and immune modulators such as cytokines and checkpoint inhibitors (CPIs). Its clinical pipeline also includes cancer immunotherapeutic candidates. Its product candidates include CX-2029, CX-904, CX-2051, CX-801 and BMS-986288. Its CX-2029 is a Probody ADC targeting CD71 for the treatment of patients with squamous non-small cell lung carcinoma (sqNSCLC) and esophageal cancers.

Webull offers CytomX Therapeutics Inc stock information, including NASDAQ: CTMX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTMX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CTMX stock methods without spending real money on the virtual paper trading platform.